http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
침습성 아스페르길루스증 진단을 위한 갈락토만난 항원 검사의 유용성 평가
송경호,장희창,전재현,박경운,박상원,최강원,오명돈,이신원,박완범 대한감염학회 2009 Infection and Chemotherapy Vol.41 No.2
Background : Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients. However, IA is difficult to diagnose, especially in the aforementioned patient group. Recently, galactomannan assay (GMA) using enzyme immunoassay has been introduced in Korea. We evaluated its diagnostic usefulness in the diagnosis of IA and we analyzed the results according to the underlying diseases. Materials and Methods : All patients who underwent GMA during the period from October 2007 to June 2008 were evaluated retrospectively. According to the criteria of European Organization for Research and Treatment of Cancer/Mycoses Study Group, IA was classified into four clinical categories: ‘proven’, ‘probable’, ‘possible’, and ‘non’ IA. Patients with ‘proven’ and ‘probable’ IA were used as the reference standards for IA. GMA was performed using Platelia Aspergillus EIA (Bio-Rad, Hercules, CA, USA). Optical density index ≥0.5 was considered positive. Results : Of the 144 patients who underwent GMA, two patients were classificed as ‘proven’ IA and sixteen patients were ‘probable’ IA. Overall sensitivity, specificity, positive predictive value, and negative predictive value of the assay were 50% (95% confidence interval [CI95], 26-74%), 88% (CI95, 81-93%), 38% (CI95, 19-59%), and 93% (CI95, 86-97%), respectively. Among the 99 patients with underlying hematologic diseases, GMA showed 67% (CI95, 35-90%) sensitivity and 89% (CI95, 80- 94%) specificity, whereas in 45 patients with underlying diseases other than hematologic diseases, sensitivity and specificity of the assay were 17% (CI95, 0-64%) and 87% (CI95, 73-96%), respectively. Conclusions : GMA showed high specificity, irrespective of the patient population. However, sensitivity of GMA was low and the assay was less sensitive in patients with underlying diseases other than hematologic diseases than in patients with hematologic diseases.
송경호,김계형,김총종,박경운,전상훈,김홍빈,김남중,오명돈,최강원 대한감염학회 2007 Infection and Chemotherapy Vol.39 No.5
Good's syndrome is the association of thymoma with immunodeficiency, characterized by hypogammaglobulinemia, B-cell lymphopenia and variably defects in cellular immunity with CD4+ T-cell lymphopenia and an inverted CD4+:CD8+ T-cell ratio. We report a 43-year-old male patient who presented with a 18-month history of productive cough and postnasal drip. One year ago, he underwent the operation for resection of a thymoma. Despite of appropriate management, sinusitis relapsed multiple times. He was found to have hypogammaglobulinemia with nearly absent B cells(4/μL). The CD4+ T-cell count was 554/μL with an inverted CD4+:CD8+ T-cell ratio of 0.6. His symptoms and signs improved with antibiotic treatment and monthly administration of intravenous immunoglobulin (IVIG, 400 mg/kg). Good 증후군은 흉선종과 면역결핍이 동반되는 질환으로, B세포의 감소로 인한 범저감마글로불린혈증과 CD4+ T세포의 감소로 인한 세포성 면역저하가 동시에 나타나는 것을 특징으로 한다. 본 증례는 18개월 전부터 발생한 반복적인 부비동염을 주소로 내원한 43세 남자 환자로, 내원 1년 전 흉선종절제수술을 시행받았으며, 면역학적 검사상 범저감마글로불린혈증과 T세포의 감소 등의 이상 소견이 발견되었다. 정주 면역글로불린과 경험적 항생제(amoxicillin/clavulanic acid) 사용 후 부비동염이 호전되었으며, 예방접종과 정기적인 면역글로불린 투여 후 특이 합병증 없이 경과 관찰 중이다.
한국 대학원 인문·사회 계열 박사과정생의 현실―연구 환경, 연구자 네트워크, 연구자 정체성과 연구 능력
송경호,김현 역사문제연구소 2023 역사비평 Vol.- No.144
This research is designed to identify the realities of doctoral students in the humanities and social sciences in South Korea by analyzing an online survey result and FGI conducted for the “Survey and Analysis to Develop Research Capacity of Doctoral Students in Humanities and Social Sciences” in 2022. Further, it analyzed the educational statistics data of South Korea. By comparing metropolitan areas and non-metropolitan areas with key factors such as (1) research environment, (2) researcher network, and (3) researcher identity and research capacities, this research can get a multi-dimensional analysis of the realities of doctoral students in the humanities and social sciences in South Korea. 이 연구는 한국의 인문·사회계열 박사과정생을 대상으로 한 설문조사 결과를 분석하여 박사과정생의 현실을 확인하기 위해 기획됐다. 2022년에 실시된 「인문·사회분야 학문후속세대의 연구력 강화를 위한 실태조사 및 과제」의 수행 과정에서 도출된 온라인 설문 조사 결과와 심층 인터뷰 결과(FGI)를 활용하였으며, 교육통계 데이터에 대한 분석을 추가적으로 시행했다. 이를 (1) 연구환경, (2) 연구자 네트워크, (3) 연구자 정체성과 연구능력을 키워드로 수도권과 비수도권을 비교해 살펴봄으로써, 인문·사회계열 박사과정생의 현실을 입체적으로 조망할 수 있었다.
송경호 대한의사협회 2022 대한의사협회지 Vol.65 No.8
Background: Antimicrobial resistance is a major global threat to public health and is associated with increased morbidity and mortality. A few therapeutic options for the treatment of multidrug resistant (MDR) gram-positive bacteria, such as methicillin resistant Staphylococcus aureus, MDR Streptococcus pneumoniae, vancomycin resistant Enterococci, are available. Current Concepts: As a result of comprehensive efforts, a dozen novel antibiotics have been developed and approved for the treatment of MDR gram-positive bacteria in the United States and Europe over the past 15 years. However, only a few antibiotics have been introduced in the Republic of Korea. The purpose of this review is to evaluate the antibiotics that act against MDR gram-positive bacteria as a primary therapeutic option. Particularly, this review focuses on novel antibiotics, including ceftaroline, ceftobiprole, telavancin, dalbavancin, oritavancin, tedizolid, delafloxacin, omadacycline, and lefamulin. Discussion and Conclusion: Novel antibiotics against MDR gram-positive bacteria have not yet been sufficiently studied in various clinical settings, and therefore, the approved indications are limited. However, these antibiotics are expected to play a major role in the treatment of MDR gram-positive bacteria owing to their advantages, including broad anti-bacterial spectrum, rapid bactericidal effect, minimal drug-drug interaction, a favorable safety profile, availability of both intravenous and oral formulations, convenient dosing scheme, and a single dose (or once a week) regimen owing to long half-life. It is crucial to introduce these novel antibiotics in the Republic of Korea for the treatment of patients suffering from MDR bacterial infections.